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Objectives: Biofilm infections of intravascular catheters caused by Staphylococcus aureus may be treated with
catheter lock solutions (CLSs). Here we investigated the antibacterial activity, cytotoxicity and CLS potential of 5-
hydroxyethyl-3-tetradecanoyltetramic acid (5HE-C14-TMA) compared with the related compounds 3-tetra-
decanoyltetronic (C14-TOA) and 3-tetradecanoylthiotetronic (C14-TTA), which are variants of quorum sensing
signalling molecules produced by Pseudomonas aeruginosa.
Methods: Antibacterial activity and mechanism of action of 5HE-C14-TMA, C14-TOA and C14-TTA were deter-
mined via MIC, bacterial killing, membrane potential and permeability assays. Susceptibility of S. aureus biofilms
formed in the presence of plasma in vitro was investigated, MTT cytotoxicity testing was undertaken and
cytokine release in human blood upon exposure to 5HE-C14-TMA and/or S. aureus biofilms was quantified. The
effectiveness of 5HE-C14-TMA as CLS therapy in vivo was assessed using a rat intravascular catheter biofilm in-
fection model.
Results: MICs of 5HE-C14-TMA, C14-TOA and C14-TTA ranged from 2 to 4 mg/L. 5HE-C14-TMA and C14-TTA
were bactericidal; all three compounds perturbed the staphylococcal membrane by increasing membrane
permeability, depolarized the transmembrane potential and caused ATP leakage. Cytotoxicity and haemolytic
activity were compound and target cell type-dependent. 5HE-C14-TMA reduced S. aureus biofilm viability in a
dose-dependent manner in vitro and in vivo and did not trigger release of cytokines in human blood, but inhibited
the high levels of IL-8 and TNF-a induced by S. aureus biofilms.
Conclusions: 5HE-C14-TMA, C14-TOA and C14-TTA are membrane-active agents. 5HE-C14-TMA was the most
potent, eradicating S. aureus biofilms at 512–1024 mg/L both in vitro and in vivo as a CLS.
Introduction
In routine healthcare, use of implantable medical devices, such as
intravascular catheters (IVC), has increased significantly. However,
colonization by surface-adhering bacteria is associated with bio-
film formation and subsequent catheter-related bloodstream in-
fection (CRBSI) resulting in significant patient morbidity and
mortality, prolonged hospitalization and excess hospital-related
costs.1,2 Staphylococcal biofilms are recognized as the most fre-
quent cause of CRBSI.3,4 Such biofilms are highly refractory to both
the innate immune system and antimicrobial therapy resulting in
treatment failure and persistence of infection.
While the presence of a Staphylococcus aureusCRBSI usually ne-
cessitates systemic antimicrobial therapy along with IVC removal,
there are common clinical situations that preclude IVC removal
such as the lack of alternative vascular access, patient
co-morbidities and bleeding disorders. An alternative treatment
approach attempting to salvage the IVC and eradicate the biofilm,
involves the combination of systemic antimicrobials and a catheter
VC The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
1 of 10
J Antimicrob Chemother
doi:10.1093/jac/dkw482
lock solution (CLS) filling the lumen of the IVC to deliver high con-
centrations of an antimicrobial at the site of infection. With respect
to staphylococcal IVC infections, the Infectious Disease Society of
America guidelines on CRBSI management recommend the use of
CLSs for IVC salvage.5 However, there is no consensus on the most
appropriate agent for use as a CLS. Several commonly used antibi-
otics and antiseptics are ineffective in the treatment of S. aureus
biofilm infections.6
Given the increasing use of medical devices and the global
threat posed by multi-antibiotic-resistant bacteria there is re-
newed interest in novel antimicrobials that inhibit bacterial growth
or control infection through attenuation of virulence and biofilm
formation.7 During a search for novel chemical scaffolds for such
compounds, we discovered that the Pseudomonas aeruginosa
quorum sensing signal molecule, N-(3-oxododecanoyl)-L-homo-
serine lactone (3-oxo-C12-HSL) inhibited S. aureus growth at high
concentrations (MIC, 100lM; 30 mg/L).8,9 At subinhibitory concen-
trations, 3-oxo-C12-HSL inhibited production of S. aureus exotoxin
virulence determinants, including a-haemolysin and toxic shock
syndrome toxin by antagonizing agr-dependent quorum sensing
probably via an allosteric interaction with the sensor kinase
AgrC.8,9 Under aqueous alkaline conditions, 3-oxo-C12-HSL can ei-
ther ring open to form the corresponding homoserine compound10
or undergo a rearrangement reaction to form 5-hydroxyethyl-3-
decanoyltetramic acid (5HE-C10-TMA).11 5HE-C10-TMA (denoted
as C10-TA)12 retains both growth and quorum sensing inhibitory
properties.9,12 It belongs to the tetramic acid (TMA) compound
class that includes diverse natural products such as reutericyclin
active against Gram-positive pathogens including staphylococci,
clostridia and streptococci.13–15 The cellular targets of the antibac-
terial TMAs range from cell wall biosynthesis, DNA topoisomerase
and RNA polymerase to membrane potential.15 5HE-C10-TMA in
common with reutericyclin dissipates the cytoplasmic membrane
potential and pH gradient, and is an iron(III) chelator.12 Serial pas-
sage of S. aureus in sub-growth inhibitory concentrations of 5HE-
C10-TMA did not select for resistance.11,12 Although active against
planktonic bacteria, 5HE-C10-TMA showed no efficacy against S.
aureus biofilms.12
Extending the C10 acyl side chain of 5HE-C10-TMA increased
potency such that the MIC and agr IC50 of 5-hydroxyethyl-3-tetra-
decanoyltetramic acid (5HE-C14-TMA) towards S. aureus were
12.5 and 14lM, respectively.9 Removal of the 5-hydroxyethyl moi-
ety of 5HE-C10-TMA to generate C10-TMA did not reduce antibac-
terial activity.9 By replacing the tetramic ring nitrogen with oxygen,
a series of 3-acyltetronic acids were generated that lack the iron-
chelating property of 5HE-C10-TMA. Of these, 3-tetradecanoylte-
tronic acid (C14-TOA) was the most potent (MIC 25lM; agr IC50
3lM). Both 5HE-C14-TMA and C14-TOA bound to the staphylococ-
cal membrane with Kd values of 4 and 2lM, respectively, and
hyperbolic binding profiles consistent with a non-co-operative sin-
gle site binding model.9 In a murine arthritis model neither C14-
TOA nor 5HE-C10-TMA were toxic, but only C14-TOA reduced the
frequency and severity of arthritis.9
Here, we build on our previous observations, by evaluating the
antibacterial and anti-biofilm potential of 5HE-C14-TMA, C14-TOA
and a novel sulphur-containing analogue (3-tetradecanoylthiote-
tronic acid; C14-TTA) towards MSSA and MRSA strains of S. aureus
using a clinically relevant in vitro and in vivo model of IVC infection
and examine their potential clinical use as CLSs.9,16
Materials and methods
Bacterial strains and growth conditions
Community-acquired MRSA (CA-MRSA) strain USA300, its isogenic agr
mutant,17 the hospital-acquired MRSA (HA-MRSA) strain BH1CC,18 the
HA-MSSA strain BH4819 and the MSSA strain SH100020 were cultured in
Mueller–Hinton broth for susceptibility testing or in RPMI-1640 (Gibco)
for biofilm formation. For the rat jugular vein catheter infection model,
the S. aureus strain USA300 (LAC) lux21 was used.
Antibacterial agents and susceptibility testing
5HE-C14-TMA and C14-TOA were synthesized as described previously9
and C14-TTA as described in the Supplementary data available at JAC
Online. Stock solutions of the compounds in DMSO at 10–50 mM were
further diluted into tissue culture media or sodium chloride for the
in vivo experiments. A DMSO solvent control was used in all in vitro ex-
periments. The following antibiotics were used: vancomycin (Vancocin;
Flynn Pharma Ltd., Republic of Ireland), daptomycin (Cubicin; Novartis,
UK), gentamicin (Hospira, UK) and tigecycline (Tygacil; Pfizer Inc.). MICs
were determined by broth microdilution in Mueller–Hinton broth, as rec-
ommended by the CLSI.
Bactericidal activity
S. aureus USA300 LAC was grown overnight in LB medium, diluted 250-fold
and grown to an OD600 0.5. Cells were diluted to 1106 per mL in challenge
medium (LB plus 5HE-C14-TMA, C14-TOA or C14-TTA at 8MIC). Samples
were removed and viable counts determined at 30 min intervals for the
first hour followed by hourly sampling. The CLSI defines a compound as
bactericidal if it reduces the starting inoculum colony count by at least
99.9% (3-logs).
Bacterial membrane permeabilization assays
Membrane permeabilization was evaluated by quantifying (i) ATP release,22
and (ii) the uptake of propidium iodide.22 S. aureus strain USA300 LAC was
grown overnight in CYGP medium,9 washed with sodium phosphate buffer
(100 mM, pH 7), re-suspended to OD600 0.1 and incubated at 37 C with a
range of concentrations of each compound for 1 h. Nisin (0.6lM) was used
as a positive control. Cell-free supernatants were assayed for ATP using the
Cell Titre-Glo kit (Promega). Staphylococcal cells were re-suspended in
100 mM sodium phosphate buffer (pH 7) containing propidium iodide
(10 mg/L), incubated in the dark at room temperature for 10 min. After
washing, propidium iodide fluorescence (excitation: 575 nm; emission
630 nm) was determined.
Dissipation of bacterial membrane potential
Transmembrane potential was determined as described by Breeuwer and
Abee23 Staphylococcal cells were resuspended in potassium phosphate
buffer (50 mM, pH 7) containing 5lM of the cationic fluorescent dye
DiSC3(5) (Invitrogen) and fluorescence determined (excitation 650 nm,
emission 680 nM).
Comparative susceptibility of S. aureus biofilms to
antimicrobials
Biofilms were formed as previously described to mimic in vivo conditions
that promote formation of coagulase-mediated biofilms.16 Briefly, micro-
titre plates or glass-bottom culture dishes (MaTek Co., USA) were coated
with either 20% (v/v) or 100% (v/v) human plasma, respectively, and inocu-
lated with S. aureus at an OD600 0.2. After 1 h, non-adherent bacteria
were aspirated, replaced with fresh RPMI-1640 and biofilms allowed to
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form over 24 h at 37 C. Pre-formed biofilms were treated for 24 h with ei-
ther 5HE-C14-TMA, C14-TOA or C14-TTA or a positive control [ethanol at
40% (v/v)]. Biofilm viability was measured by (i) resazurin-conversion assay
(in microtitre wells), or (ii) live/dead imaging (glass-bottom dishes).
Conversion of the non-fluorescent redox dye, resazurin into the fluorescent
resorufin was performed as described previously.16 A 44lM resazurin
(Sigma-Aldrich, UK) solution in RPMI-1640 was added to an equal biofilm
volume and incubated for 1 h at 37C. Fluorescence (excitation 544 nm,
emission 590 nm) was quantified using a Perkin Elmer 2030 Multilabel
Reader VictorTM X3. Biofilms were stained with SYTO9 Green (at 13.36lM)
and propidium iodide (at 80lM) (Molecular ProbesV
R
) for 1 h prior to wash-
ing. Four representative images at40 and100 were obtained per experi-
mental group, per experiment using a Zeiss LSM 510 META confocal
microscope. Each experiment was repeated at least three times.
Fluorescence intensity was quantified using Image J1 software (http://
imagej.net/Welcome).
MTT cell viability assay
Human keratinocyte (HaCaT) cells were cultured in DMEM supple-
mented with 10% (v/v) FBS. Primary human umbilical vein endothelial
cells (HUVECs) were cultured in EGMTM-2 Bulletkit (Lonza) medium.
HaCaT and HUVECs were harvested using TrypLETM Express (Gibco). Cells
were seeded in microtitre plates at 3105 cells/mL and incubated for
24 h at 37 C with an antimicrobial compound (up to 10 mg/L) or Triton
X100 at 1% (v/v). After removing the medium, cells were incubated with
500 mg/L MTT (Sigma-Aldrich) for 4 h. The crystals formed were solubi-
lized with DMSO. Absorbance was recorded at 560 nm and the CC50 was
determined.
Haemolysis assay
Human blood containing EDTA (1.6 g/L) was centrifuged at 1000 g for
5 min. Red blood cells (RBC) were washed twice with PBS, diluted 2-fold and
incubated with compounds or Triton X100 (positive control) at 0.5% (v/v).
A570 was determined to quantify haemolysis. IC50s were derived from the
corresponding dose–response curves.
Cytokine release assay
EDTA-treated human blood was incubated in microtitre wells containing ei-
ther S. aureus USA300 biofilm, 5HE-C14-TMA (at 256 mg/L) only or biofilm
with 5HE-C14-TMA (at 256 mg/L) and incubated for 2 h at 37 C. Plasma
samples were collected by centrifugation (1000 g) and assayed for human
cytokines using a Bio-Plex 200 (Bio-Rad). A standard curve was employed to
maximize sensitivity for samples containing low cytokine levels. At least
three different donor blood samples (with three replicates for each) were
used.
Rat IVC infection model
Rats (male, Sprague–Dawley) were pre-implanted with jugular vein polyur-
ethane catheters (13.5 cm long, outside diameter 1.1 mm, inside diameter
0.6 mm) (Charles River, UK). Daily flushing was performed with 150lL so-
dium chloride [0.1% (w/v)] following introduction of 40lL heparin (100 IU),
sodium chloride 0.1% (w/v) within the lumen. IVC-biofilm infection was de-
veloped as previously reported.24–26 Catheters were inoculated with 40lL
S. aureus USA300lux suspension at 1104 cfu/mL ‘locked’ within the cath-
eter for 1 day. Intravenous vancomycin (50 mg/kg) was administered twice
daily at 12 h intervals to prevent systemic spread of infection. CLS consisting
of 5HE-C14-TMA (40lL) at 512 mg/L in sodium chloride 0.1% (w/v) was ad-
ministered daily for 5 days upon development of infection. After 5 days of
treatment, catheters were removed and luminescence imaged using a
Perkin Elmer IVIS Spectrum instrument (exposure, 20 s; binning: 4, f1).
Bacteria were harvested from the catheters by treatment with TrypLETM
Express (Gibco) and washing prior to determining viable counts.
Ethics approval
Ethics approvals for blood collection and use (REC820 and REC951) and ani-
mal experiments (REC931) were granted by the Ethics Committee of the
Royal College of Surgeons in Ireland. In vivo procedures were approved by
Health Products Regulatory Authority and performed under Irish
Government Department of Health guidelines.
Statistics
Statistical significance was assessed using one-way ANOVA except for
Figure 6 where an unpaired t-test was applied. Statistical significance was
indicated as *P<0 .05, **P<0.001 and ***P<0.0001.
Results
Bactericidal activity of 5HE-C14-TMA, C14-TOA and C14-
TTA
5HE-C14-TMA, C14-TTA and C14-TOA (Figure 1a) each inhibited
growth of MRSA (USA300 JE2 and BH1CC) and MSSA (SH1000 and
BH48) strains with MICs from 2 to 4 mg/L (Table 1). 5HE-C14-TMA
and C14-TTA, but not C14-TOA, were bactericidal (Figure 1b); at
8MIC, 5HE-C14-TMA reduced the viability of USA300 by 3 logs
over 30 min.
5HE-C14-TMA, C14-TTA and C14-TOA perturb the
S. aureus cytoplasmic membrane
5HE-C14-TMA and C14-TOA (a tetronic acid analogue lacking the
5-hydroxyethyl substituent) both bind to S. aureus membranes
with high affinity.9 Lowery et al. showed that 5HE-C10-TMA could
dissipate the cytoplasmic transmembrane potential (DW).12 To de-
termine whether 5HE-C14-TMA, C14-TTA and C14-TOA exhibit
similar modes of action, the change in membrane potential follow-
ing exposure to each compound was determined using the cat-
ionic fluorescent dye DiSC3(5). 5HE-C14-TMA (30lM) caused an
increase in fluorescence, indicative of membrane depolarization
(Figure 2a). Similar results were obtained for C14-TTA and C14-
TOA (Figure S1, available as Supplementary data at JAC Online). To
investigate the extent of membrane perturbation caused by 5HE-
C14TMA and related compounds, the uptake of propidium iodide
in conjunction with the loss of the cytoplasmic ATP was assessed.
Figure 2(b and c) shows that propidium iodide fluorescence and
extracellular ATP levels increased with increasing concentrations
of each compound, suggesting loss of membrane integrity is the
likely cause of bacterial cell death. For both assays, C14-TTA was
the least active.
Biofilm killing activity
The biofilm-killing activity of 5HE-C14-TMA, C14-TOA and C14-TTA
against in vivo-relevant biofilms of S. aureus was compared with
clinically relevant antibiotics. Although all three compounds
reduced biofilm viability, C14-TOA and C14-TTA were only active at
the highest concentrations (512 and 1024 mg/L) reducing viability
by 2.5–3-fold (Figure 3). In contrast, 5HE-C14-TMA (at 1024 mg/
L) effectively eradicated biofilm reducing viability by 7–20-fold
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depending on the strain (Figure 3). This activity profile was similar
to that of vancomycin although the latter only reduced MRSA bio-
film viability by3.5–4-fold at 1024 mg/mL (Figure 3). In contrast,
daptomycin was the most active antimicrobial evaluated (Figure
3). The in vitro activity of 5HE-C14-TMA was further validated using
live/dead staining. Figure 4 confirms the dose-dependent loss of
viability of S. aureus USA300 and SH1000 biofilms and shows that
substantial killing (>50%) occurs with as little as 128 mg/L for both
strains.
Cytotoxicity and haemolytic activity
To obtain comparative cytotoxicity data for 5HE-C14-TMA, C14-
TOA and C14-TTA, we examined the responses of HaCaT keratino-
cytes and primary HUVEC cells using the MTT viability assay. Table
2 shows that C14-TTA (CC50 26lM) is more cytotoxic for HaCaT
cells than 5HE-C14-TMA (CC50 181lM) or C14-TOA (CC50 257lM).
For HUVECs, 5HE-C14-TMA and C14-TOA showed similar CC50s
(Table 2). In contrast, C14-TOA was far less haemolytic towards
human RBC (CC50 >2048lM/>667 mg/L) than C14-TTA or 5HE-
C14-TMA (Table 2). The ‘selectivity index’ (SI) of a given agent pro-
vides a measure of the preference for bacterial rather than mam-
malian cells and is defined as the ratio of mammalian cell
cytotoxicity to MIC (CC50/MIC).
27 Compounds with SI values >10
are usually considered suitable for in vivo evaluation. For HaCaT
cells, SI values of 32, 20 and 2, respectively, were obtained for
5HE-C14-TMA, C14-TOA and C14-TTA suggesting that 5HE-C14-
TMA shows the greatest selectivity. 5HE-C14-TMA and C14-TOA
showed less selective toxicity towards HUVECs with SIs 3.5 and
2.3, respectively.
5HE-C14-TMA treatment reduces release of pro-
inflammatory cytokines
Cytokine levels in whole human blood were quantified upon ex-
posure to S. aureus USA300 biofilm, 5HE-C14-TMA, or the biofilm
with 5HE-C14-TMA.16 The levels of the pro-inflammatory IL-8 and
TNF-a were significantly elevated in the blood exposed to biofilm
while IL-2, IL-4, IL-6, IL-10, GM-CSF and IFN-c remained un-
changed (Figure 5 and data not shown). There was no increase in
cytokine levels for the sample containing the agent only.
However, exposure of the same biofilm to a sub-bactericidal dose
(256 mg/L for 2 h) of 5HE-C14-TMA resulted in substantial reduc-
tions in IL-8 and TNF-a. These data suggest that 5HE-C14-TMA
modifies the immunogenicity of S. aureus biofilms (Figure 5).
Given that 5HE-C14-TMA inhibits the S. aureus agr quorum sensing
system, we examined the cytokine levels produced in response to
an S. aureus USA300 agr mutant biofilm treated with or without
5HE-C14-TMA. The data presented in Figure S2 show that, while
both IL-8 and TNF-a are significantly reduced in response to the
agr mutant biofilm, the same dose of 5HE-C14-TMA had no fur-
ther effect on the levels of the two cytokines.
In vivo activity of 5HE-C14-TMA against S. aureus
biofilm
The efficacy of 5HE-C14-TMA as a CLS in an in vivo rat model of IVC
infection using the MRSA strain USA300lux was investigated
(Figure 6). Animals treated with CLS containing sodium chloride
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Figure 1. (a) Chemical structures of 5HE-C14-TMA, C14-TOA and C14-TTA. (b) Planktonic S. aureus USA300 cells were treated with 8MIC of 5HE-
C14-TMA, C14-TOA or C14-TTA, respectively, or a DMSO solvent control. Data presented are the mean viable counts (cfu) per mL from three inde-
pendent experiments (6SD).
Table 1. MICs of 5HE-C14-TMA, C14-TOA and C14-TTA for MRSA
(USA300 and BH1CC) and MSSA (SH1000 and BH48) strains
Compound
MIC [lM (mg/L)] for S. aureus strain
USA300 BH1CC SH1000 BH48
5HE-C14-TMA 6.25 (2) 6.25 (2) 6.25 (2) 6.25 (2)
C14-TOA 12.5 (4) 12.5 (4) 12.5 (4) 12.5 (4)
C14-TTA 12.5 (4) 12.5 (4) 12.5 (4) 12.5 (4)
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[0.1% (w/v)] were colonized by109 cfu/mL at day 5 of the treat-
ment regimen while in catheters treated with 5HE-C14-TMA the
biofilm was effectively eradicated, suggesting in vivo efficacy of
the compound.
Discussion
An important treatment option for the salvage of an IVC in pa-
tients with a CRBSI due to S. aureus is the use of a CLS in combin-
ation with systemic antibiotics.5 In choosing an antimicrobial
agent for the CLS, consideration must be given to the likely effect-
iveness of the agent against S. aureus biofilms in the context of
the environmental conditions in which such biofilm is formed.6
We recently developed an in vitro biofilm model of IVC infection
employing physiologically relevant iron-deficient RPMI-1640 me-
dium in conjunction with human plasma-conditioned surfaces
which generate coagulase-mediated and fibrin-embedded bio-
films that mimic those formed in vivo. These biofilms, unlike those
formed in rich laboratory media under standard conditions dem-
onstrated antibiotic susceptibilities similar to those found for
in vivo infections established by S. aureus biofilms.6,16 Given the
need for novel and effective agents for the treatment of device-
related S. aureus infections that could be used as CLS or as poten-
tial treatment options for other device-related infections, we
explored the mode of action and inhibitory activity of compounds
that are related to a natural product (5HE-C10-TMA).11 This nat-
ural product is formed in vivo during chronic P. aeruginosa lung in-
fections in individuals with cystic fibrosis and may well contribute
to the eradication of competitor bacteria including S. aureus.12,28
Although 5HE-C10-TMA inhibits the growth of planktonic Gram-
positive bacteria, it was reported to lack activity against S. aureus
biofilms formed in rich laboratory media on polystyrene.9,12,29
Similarly, 5HE-C10-TMA was inactive in a murine arthritis infection
model.9 Consequently we synthesized a series of TMAs and
related compounds to provide a structure–function relationship
(SAR) and to identify compounds with greater antibacterial and
anti-biofilm activity.9
The most active TMA identified in our SAR study was the C14
analogue of 5HE-C10-TMA that exhibited an 8-fold increase in
growth inhibitory activity against planktonic S. aureus.9 These
data are also consistent with a reutericyclin SAR study that re-
vealed that lipophilic analogues were generally more active
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Figure 2. Perturbation of staphylococcal cytoplasmic membrane structure and function by 5HE-C14-TMA, C14-TTA and C14-TOA. (a)
Depolarization of transmembrane potential by 5HE-C14-TMA. (1) Cationic fluorescent dye DiSC3(5) was added to cells followed (2) by glucose
(10 mM), (3) nigericin (5lM) to abolish the pH gradient and (4) 5HE-C14-TMA (30 lM). Complete depolarization of the membrane potential was
achieved by the addition of 5lM valinomycin (5). Experiments were carried out on three independent occasions with representative data pre-
sented. (b) Cytoplasmic ATP release relative to the positive control (nisin, 0.6 lM) of S. aureus cells treated with (from left to right) 0, 5, 10, 25, 50
and 100lM 5HE-C14-TMA, C14-TTA or C14-TOA. (c) Membrane permeability. The percentage of propidium iodide uptake relative to the positive
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by 5HE-C14-TMA, C14-TTA, C14-TOA or the antibiotics vancomycin, daptomycin or gentamicin. S. aureus biofilms were grown in plasma-coated
microtitre plate wells in RPMI-1640 for 24 h at 37 C. 5HE-C14-TMA, C14-TOA or C14-TTA (or antibiotics) were incubated in the wells at a range of con-
centrations for 24 h. Resazurin-conversion assay was used to assess biofilm viability. Mean fluorescence intensities (6SD) of three independent
experiments are shown.
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against Gram-positive pathogens than those containing polar
and charged substituents.15 Since ferric iron was reported to
abolish the antibacterial activity of 5HE-C10-TMA towards
Clostridium difficile29 we also synthesized variants of the TMAs
in which we extended the acyl chain and replaced the ring nitro-
gen with oxygen or sulphur to generate the C14 tetronic (TOA)9
and thiotetronic (TTA; this paper) acids that in contrast to the
TMAs, do not chelate iron (data not shown). The MICs of C14-
TOA and C14-TTA at 4 mg/L were marginally higher than 5HE-
C14-TMA (2 mg/L) for the MRSA and MSSA strains investigated.
However, only 5HE-C14-TMA and C14-TTA were bactericidal in
time-dependent killing assays at 8MIC against the CA-MRSA
strain USA300 LAC. Consistent with their ability to bind to the S.
aureus membrane with high affinity, 5HE-C14-TMA, C14-TOA
and C14-TTA in common with 5HE-C10-TMA and antibiotics
such as reutericyclin, daptomycin and telavancin dissipate the
transmembrane potential, increase cellular permeability and
promote the release of ATP.9,12,22,30 For 5HE-C10-TMA, dissipa-
tion of the transmembrane potential and pH gradient rather
than membrane permeabilization were suggested to correlate
most closely with bacterial cell death.
5HE-C10-TMA and 5HE-C12-TMA have been suggested to be
non-toxic to human cells since neither reduced the viability of
bone marrow-derived macrophages up to 100lM.12 However, we
observed that the cytotoxicity of 5HE-C14-TMA, C14-TOA and C14-
TTA was cell type dependent. For example, 5HE-C14-TMA reduced
the viability of HUVEC cells at much lower concentrations than for
HaCaT cells. Nevertheless the SIs for 5HE-C14-TMA indicates that
this compound is more selective for bacteria than mammalian
cells.
Although 5HE-C10-TMA was inactive at 200 mg/L against S.
aureus biofilms,12 we observed that the longer chain analogue,
5HE-C14-TMA killed over 50% of both MRSA and MSSA biofilms at
128 mg/L with complete killing achieved at 512–1024 mg/L.
However, the differences observed may not only reflect the
increased anti-biofilm activity of 5HE-C14-TMA compared with
untreated
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Figure 4. Dose-dependent killing of S. aureus USA300 and SH1000 biofilms by 5HE-C14-TMA. Bacterial biofilms were grown in plasma-coated
glass-bottom MaTeKTM dishes in RPMI-1640 for 24 h at 37 C. 5HE-C14-TMA was added at a range of concentrations and incubated for a further
24 h. Biofilm bacterial viability was evaluated using live/dead imaging (top panels), quantified using ImageJ and presented as mean fluorescence
intensity (6SD) (left histogram, USA300; right histogram, SH1000).
Table 2. Cytotoxic and haemolytic activities of 5HE-C14-TMA, C14-TOA
and C14-TTA
Cell type
CC50 [lM (mg/L)]
5HE-C14-TMA C14-TOA C14-TTA
HaCaT 181 (64) 257 (80) 26 (8.3)
HUVEC 19 (7) 28 (9) not determined
RBC 246 (87) >2048 (>667) 470 (153)
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5HE-C10-TMA, achieved via the four carbon acyl chain extension,
but also the nature of the biofilm model used as a more in-vivo-
like model of biofilm infection was used in this study. In contrast
to 5HE-C14-TMA, and despite the similarities with respect to MIC
and mechanism of action, C14-TOA and C14-TTA were far less
effective at reducing the viability of either MSSA or MRSA biofilms.
Since 5HE-C14-TMA, in contrast to C14-TOA and C14-TTA, is an
iron chelator and as iron availability impacts on S. aureus biofilm
development,31 the differential anti-biofilm activity observed
may be due in part to this additional functionality.
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Figure 5. Human IL-8 and TNF-a concentrations in whole human blood following exposure to 5HE-C14-TMA (256 mg/L), untreated USA300 biofilm
or USA300 biofilm treated with 5HE-C14-TMA (256 mg/L) for 2 h. Supernatants were collected and the plasma fraction subjected to a Bio-Plex
Precision ProTM (magnetic) human cytokine immunoassay (Bio-Rad). Means of cytokine concentrations obtained from three donors (6SD) are
shown. Statistical significance was determined using one-way ANOVA and is indicated (*P<0.5). h, human.
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Figure 6. In vivo eradication of an MRSA biofilm with 5HE-C14-TMA. CLS consisting of 5HE-C14-TMA (512 mg/L) was instilled into a jugular vein catheter
to treat IVC-associated S. aureus USA300lux biofilms. In the control group the CLS was replaced with 0.9% sodium chloride. CLS was renewed every
24 h for 5 days. The day after the final treatment, animals were sacrificed, catheters removed and subjected to quantification of bioluminescence
using IVIS. Bacterial cells were harvested using TrypLETM reagent, serially diluted and plated on tryptic soy agar for cfu counting. Statistical significance
is indicated (***P<0.001). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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The reduced anti-biofilm activity of C14-TOA compared with
5HE-C14-TMA is interesting given that C14-TOA significantly
reduced the frequency and severity of arthritis and joint destruc-
tion in the same murine S. aureus infection model in which 5HE-
C10-TMA was inactive.9 C14-TOA did not, however, reduce the
numbers of viable staphylococci in the kidneys suggesting that the
anti-virulence properties of the molecule as an agr inhibitor may
account for the positive outcome on arthritis observed. Although
5HE-C14-TMA is a less effective agr inhibitor than C14-TOA,9
S. aureus biofilms treated with sub-growth inhibitory 5HE-C14-
TMA did not elicit production of IL-8 and TNF-a when exposed to
human blood. This was also the case for agr mutant biofilms sug-
gesting that 5HE-C14-TMA modifies the immunogenicity of S. aur-
eus biofilms by inhibiting the production and release of agr-
dependent pro-inflammatory toxins.32
Encouragingly, 5HE-C14-TMA was effective in the eradication
of MRSA and MSSA biofilms formed in vitro, but under in vivo-mim-
icking conditions. To extend our in vitro findings a rat model of IVC
infection assessed the effectiveness of 5HE-C14-TMA in vivo. 5HE-
C14-TMA was highly effective in the eradication of MRSA biofilm
formed in this model, whilst untreated catheters resulted in har-
vesting of 109 cfu/mL biofilm.
Taken together, the in vitro and in vivo efficacy of 5HE-C14-TMA
towards S. aureus biofilms suggests that this compound scaffold
has therapeutic potential for the treatment of S. aureus IVC infec-
tions within a CLS.
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Synthesis	of	3-Tetradecanoylthiotetronic	acid	(C14-TTA)	
The	chemical	synthesis	of	3-tetradecanoylthiotetronic	acid	(C14-TTA)	was	accomplished	in	5	
steps	as	shown	in	Scheme	1.	Thioglycolic	acid	was	acetylated	with	acetic	anhydride	and	the	
S-acetylated	product	was	condensed	with	Meldrum’s	acid	using	water	soluble	carbodiimide	
to	give	5-acylated	Meldrum’s	acid	as	a	orange	brown	solid.		The	latter	when	refluxed	in	
methanol	gave	a	β-keto	ester,	methyl	4-(acetylthio)-3-oxobutanoate	as	a	brown	oil.	The	β-
keto	ester	was	then	acylated	with	tetradecanoyl	chloride	using	sodium	hydride	to	afford	
methyl	2-[2-(acetylthio)acetyl]-3-oxohexadecanoate	as	a	yellow	solid	after	chromatographic	
purification.		The	yellow	solid	when	dissolved	in	a	solution	of	sodium	hydroxide	and	stirred	
overnight	underwent	S-deacetylation	and	subsequent	cyclization	to	deliver	C14-TTA	as	a	
purple	solid	after	purification.	
		
2-(Acetylthio)acetic	acid	
Acetic	anhydride	(3.24	g/3	mL,	31.7	mmol)	was	added	to	a	solution	of	thioglycolic	acid	(2.64	
g≡2	mL,	28.7	mmol)	in	acetonitrile	(20	mL)	containing	triethylamine	(5.81	g≡8	mL,	57	mmol)	
and	4-dimethylaminopyridine	(0.01	g)	at		0oC.	The	mixture	was	stirred	overnight	at	room	
temperature.	The	solvent	was	removed	under	reduced	pressure	and	the	resulting	residue	
was	taken	up	in	1	M	HCl	(30	mL)	and	extracted	with	ethyl	acetate	(2x	25	mL).	The	combined	
organic	layer	was	washed	with	water	(20	mL)	and	brine	(20	mL),	dried	over	magnesium	
sulphate	and	concentrated	to	give	a	clear	oil	which	was	then	dried	in	a	desiccator	to	remove	
traces	of	acetic	acid	(2.712	g,	70.4%).	
1H	NMR	(CDCl3)	δ	2.45	(3H,	s,	Me),	3.76	(2H,	s,	CH2)	
S-(2-(2,2-Dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxoethyl)	ethanethioate	
A	mixture	of	2-(acetylthio)acetic	acid	(2.709	g,	20.2	mmol),	4-dimethylaminopyridine	(3.69	g,	
30.3	mmol)	and	Meldrum’s	acid	(3.05	g,	21.2	mmol)	in	dry	dichloromethane	(40mL)	was	
	
	
stirred	at	room	temperature.	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl	(4.26	g,	
22.2	mmol)	and	triethylamine	(2.04	g≡2.81	mL,	20.2	mmol)	were	added	and	the	mixture	was	
stirred	overnight	at	room	temperature.	The	solution	was	then	washed	with	1	M	HCl	(2x	30	
mL)	and	brine	(20	mL).	The	organic	layer	was	dried	over	magnesium	sulphate	and	
concentrated	to	give	an	orange	brown	solid.	(4.291	g,	81.6%)	
1H	NMR	(CDCl3)	δ	1.81	(6H,	s,	Me	x	2),	2.45	(3H,	s,	Me),	3.76	(2H,	s,	CH2)	
Methyl	4-(acetylthio)-3-oxobutanoate	
A	solution	of	S-(2-(2,2-Dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxoethyl)	ethanethioate	(4.288	
g)	and	dry	methanol	(40	mL)	was	stirred	at	reflux	for	2	h.	The	mixture	was	cooled	and	
concentrated,	dissolved	in	ethyl	acetate	(50	mL),	then	washed	with	saturated	sodium	
bicarbonate	(25	mL),	1	M	HCl	(25	mL),	and	brine	(25	mL).	The	organic	layer	was	dried	over	
magnesium	sulphate	and	concentrated	to	give	a	brown	oil.	(2.275	g,	72.8%)	
1H	NMR	(CDCl3)	δ	2.40	(3H,	s,	Me),	3.63	(2H,	s,	COCH2CO),	3.78	(3H,	s,	OMe),	3.88	(2H,	s,	
CH2S)	
Methyl	2-(2-(acetylthio)acetyl)-3-oxohexadecanoate	
A	solution	of	methyl	4-(acetylthio)-3-oxobutanoate	(0.065	g,	3.5	mmol)	in	dry	toluene	(4	mL)	
was	added	to	a	slurry	of	sodium	hydride	[60%	dispersion	in	mineral	oil]	(0.154	g,	3.85	mmol)	
at	room	temperature	over	15	min.	The	mixture	was	stirred	at	room	temperature	for	1	h	and	
then	a	solution	of	tetradecanoyl	chloride	(0.684	g≡0.951	mL,	3.5	mmol)	in	dry	toluene	(4	mL)	
was	added	over	10	min.	The	stirring	was	continued	at	room	temperature	for	24	h.	The	
mixture	was	then	washed	with	water	(2x	10	mL),	1	M	HCl	(2x	10	mL),	and	brine	(10	mL).The	
organic	layer	was	dried	over	magnesium	sulphate	and	concentrated	to	give	an	oily	brown	
solid	which	was	purified	using	Flash	chromatography	(5%	ethyl	acetate	in	hexane)	to	deliver	
the	title	compound	as	a	yellow	solid	(0.406	g,	29%)	
1H	NMR	(CDCl3)	δ	0.92	(3H,	t,	Me),	1.28-1.34	(20H,	m,	(CH2)10Me),	1.66	(2H,	m,	
CH2(CH2)10Me),	2.40	(3H,	s,	COMe),	2.69	(2H,	t,	CH2(CH2)11Me),	4.08	(3H,	s,	OMe),	4.15	(2H,	s,	
CH2S)	
3-Tetradecanoylthiotetronic	acid	
A	solution	of	sodium	hydroxide	(0.08	g,	2	mmol)	in	water	(2.0	mL)	was	added	to	methyl	2-(2-
(acetylthio)acetyl)-3-oxohexadecanoate	(0.402	g,	1.0	mmol)	in	THF	(5	mL)	and	stirred	
overnight	at	room	temperature.	The	THF	was	removed	under	vacuum,	acidified	the	residue	
with	1	M	HCl	(4	mL)	and	extracted	into	ethyl	acetate	(2x	15	mL).	The	organic	layer	was	
washed	with	brine	(10	mL),	dried	over	magnesium	sulphate	and	concentrated	to	give	a	
brown	solid	which	was	purified	using	Flash	chromatography	(80%	ethyl	acetate	in	hexane)	to	
deliver	the	title	compound	as	a	purple	solid.	(0.061	g,	18.8%)	
1H	NMR	(DMSO)	δ	0.86	(3H,	t,	Me),	1.24-1.30	(20H,	m,	(CH2)10Me),	1.41	(2H,	m,	
CH2(CH2)10Me),	2.68	(2H,	s,	CH2(CH2)11Me),	3.44	&	3.70	(2H,	s	x2)	
ES-MS	m/z	325.1839	[M-H]-,	C18H29O3S	requires	325.1843.	
	
	
	
Figure	S1.	Perturbation	of	staphylococcal	cytoplasmic	membrane	structure	Depolarisation	of	
transmembrane	potential	by	(a)	C14-TOA	and	(b)	C14-TTA.	(1)	The	cationic	fluorescent	dye	
DiSC3(5)	was	added	to	cells	followed	(2)	by	glucose	(10	mM),	(3)	nigericin	(5	µM)	to	abolish	
the	pH	gradient	and	(4)	either	C14-TOA	or	C14-TTA	(30	µM).	Complete	depolarisation	of	the	
membrane	potential	was	achieved	by	the	addition	of	5	µM	valinomycin	(5).	Experiments	
were	carried	out	on	3	independent	occasions	with	representative	data	presented.	
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Figure	S2.	Human	IL-8	and	TNFα	concentrations	in	whole	human	blood	following	exposure	of	
coagulase-dependent	biofilms	of	the	S.	aureus	USA	300	wild	type	and	isogenic	agr	mutant	to	
5HE-C14-TMA	(256	µg/mL)	or	solvent	control.	The	means	of	cytokine	concentrations	
obtained	for	three	donors	±	SDs	are	shown.	Statistical	significance	was	determined	using	
one-way	ANOVA.	
			
	
	
	
	
